# Online Wolverine — A reading room for the BPC-157 + TB-500 literature > Editorial summaries of the peer-reviewed research on the BPC-157 + TB-500 peptide blend popularly nicknamed the Wolverine stack. Mechanism, animal evidence, sparse human data, regulatory status. An editorial reading of the published research on the BPC-157 + TB-500 blend — what the studies actually report, where the evidence ends, and what the online folklore added on top. ## The short version The Wolverine blend is a research-community nickname for two synthetic peptides — BPC-157 and TB-500 — used together. Neither is approved by the U.S. FDA for any human purpose. The evidence base lives almost entirely in rodent studies, with only a handful of small human pilots for each component and none at all for the combination. BPC-157 (15 amino acids, derived from a sequence in human gastric juice) works chiefly on blood-vessel growth and connective-tissue repair. TB-500 (a 7-amino-acid fragment of thymosin beta-4) works on the cell's internal scaffolding — specifically the actin filaments that drive cell movement and tissue remodeling. The case for combining them rests on those non-overlapping mechanisms, not on a study that tested them together. What the research community reports — faster injury recovery, less joint pain, gut comfort — is anecdotal, not clinical evidence. Serious questions remain about long-term safety, product purity from unregulated suppliers, and a theoretical concern around the blend's pro-angiogenic activity in cancer contexts. The [effects page](/effects) goes deeper on what people say and what the safety literature cautions. ## What this publication is The blend exists on the internet before it exists in a journal. Forum threads, podcast asides, late-2010s message-board lore — the so-called Wolverine stack was nicknamed in those rooms, not in a clinical trial. Online Wolverine is the opposite kind of room. It reads the published research on the two component peptides — BPC-157 and TB-500 — and indexes it for anyone trying to understand what the literature actually shows, separated from what the forums claim. What the literature shows, in one line: BPC-157 is a 15-amino-acid peptide derived from a sequence found in human gastric juice, studied in rats for tendon, ligament, muscle, and gastrointestinal repair [1][2][3]. TB-500 is a synthetic fragment of the 43-amino-acid endogenous peptide thymosin beta-4 (Tβ4), carrying the LKKTETQ actin-binding motif, studied for cell-migration and wound-healing effects [9][12]. Neither is approved by the U.S. Food and Drug Administration for any human indication, and no controlled in-vivo study has tested the combination against either peptide alone [18]. That last sentence is the most important one on this site. ## Why "Wolverine" The nickname is community folklore, not a brand and not a clinical designation. It seems to have attached itself to the BPC-157 + TB-500 blend because both component peptides are reported, in preclinical models, to accelerate tissue repair — and "the regenerative one" needed a shorter name to type into a search bar. The character the nickname borrows from belongs to a separate intellectual-property universe that has nothing to do with peptide research, and this publication takes no position on it. We use "the BPC-157 + TB-500 blend" or "the regenerative peptide stack" in body copy and reserve the nickname for moments where its search relevance earns it a mention. The other word in the domain — "online" — is also doing literal work. This is a reading room online. It is not an online clinic, an online pharmacy, or an online dispensary. The /about page is explicit about what the publisher is and is not. ## What the research actually reports BPC-157 has been studied principally by the Sikiric laboratory in Zagreb across two decades. The most-cited rodent papers report that intraperitoneal BPC-157 at 10 μg/kg accelerated Achilles tendon-to-bone healing in rats with measurable improvements in load-to-failure and collagen organization, and partially offset corticosteroid-induced healing impairment [1]. A separate program of work reported improved medial collateral ligament healing at 90 days across intraperitoneal, topical, and oral routes [2]. A muscle-crush-injury study reported normalization of creatine kinase, LDH, AST, and ALT alongside reduced hematoma at 14 days [3]. Vascular work in rat aortic rings and human umbilical vein endothelial cells reported endothelium-dependent vasodilation and activation of the Src–Caveolin-1–eNOS signaling pathway [4]. The plasma half-life is reported as under 30 minutes [16]. Thymosin beta-4 — the parent peptide of TB-500 — has the more substantial human evidence. A randomized Phase III trial of 0.1% RGN-259 (Tβ4) ophthalmic solution for neurotrophic keratopathy reported complete corneal healing in 6 of 10 treated subjects versus 1 of 8 placebo at day 29 [14]. A Phase 2 dry-eye trial reported 35.1% reduction in ocular discomfort and 59.1% reduction in corneal staining at day 56 [15]. In cardiac models, Tβ4 has been reported to activate integrin-linked kinase, mobilize adult epicardial progenitors, and improve function after experimental myocardial infarction [9][10]. In a rat embolic-stroke model, Tβ4 at 6 mg/kg improved functional outcome via axonal and vascular remodeling [11]. What the literature does not contain is a controlled in-vivo study of the blend itself. The combination has been written about extensively online and discussed in mechanistic reviews [18], but the synergy claim is an extrapolation from non-overlapping mechanisms — not a measured outcome. ## Where to begin The four signposted entry points: - **/research** — the literature itself, indexed and annotated. The mechanistic split between BPC-157 (angiogenesis, VEGFR2, eNOS) and TB-500 (G-actin sequestration, ILK, cell migration) is the spine of the page. - **/dosage** — what the research-context doses look like in the published rodent and human ophthalmic protocols. Not a prescription. Not a how-to. A reading of what was tested. - **/faq** — the twelve questions that turned up most often in the search-intent corpus, answered with citations rather than opinion. - **/references** — the full citation list, with DOIs, PubMed IDs, and links to the open-access full texts where they exist. The /about page explains the publisher, the editorial standards, and the disclaimer in more detail. --- An editorial reading of the published research — not a clinic, not a vendor, not medical guidance.